124 related articles for article (PubMed ID: 37863157)
1. Primary tumor-induced immunity suppresses bone metastases of breast cancer in syngeneic immunocompetent mouse models.
Hiraga T; Nishida D; Horibe K
Bone; 2024 Jan; 178():116944. PubMed ID: 37863157
[TBL] [Abstract][Full Text] [Related]
2. Primary tumor-induced immunity eradicates disseminated tumor cells in syngeneic mouse model.
Piranlioglu R; Lee E; Ouzounova M; Bollag RJ; Vinyard AH; Arbab AS; Marasco D; Guzel M; Cowell JK; Thangaraju M; Chadli A; Hassan KA; Wicha MS; Celis E; Korkaya H
Nat Commun; 2019 Mar; 10(1):1430. PubMed ID: 30926774
[TBL] [Abstract][Full Text] [Related]
3. CD8
Monteiro AC; Bonomo A
Bone; 2021 Sep; 150():116014. PubMed ID: 34022456
[TBL] [Abstract][Full Text] [Related]
4. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
6. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
7. COPS6 promotes tumor progression and reduces CD8
Du WQ; Zhu ZM; Jiang X; Kang MJ; Pei DS
Acta Pharmacol Sin; 2023 Sep; 44(9):1890-1905. PubMed ID: 37095198
[TBL] [Abstract][Full Text] [Related]
8. Models of bone metastasis.
Campbell JP; Merkel AR; Masood-Campbell SK; Elefteriou F; Sterling JA
J Vis Exp; 2012 Sep; (67):e4260. PubMed ID: 22972196
[TBL] [Abstract][Full Text] [Related]
9. Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.
Zhang F; Dong W; Zeng W; Zhang L; Zhang C; Qiu Y; Wang L; Yin X; Zhang C; Liang W
Breast Cancer Res; 2016 Apr; 18(1):38. PubMed ID: 27036297
[TBL] [Abstract][Full Text] [Related]
10. Primary and metastatic breast tumors cross-talk to influence immunotherapy responses.
Oliver AJ; Keam SP; von Scheidt B; Zanker DJ; Harrison AJ; Tantalo DG; Darcy PK; Kershaw MH; Slaney CY
Oncoimmunology; 2020 Aug; 9(1):1802979. PubMed ID: 32939322
[TBL] [Abstract][Full Text] [Related]
11. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.
Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A
PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195
[TBL] [Abstract][Full Text] [Related]
13. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
[TBL] [Abstract][Full Text] [Related]
14. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model.
Mathenge EG; Dean CA; Clements D; Vaghar-Kashani A; Photopoulos S; Coyle KM; Giacomantonio M; Malueth B; Nunokawa A; Jordan J; Lewis JD; Gujar SA; Marcato P; Lee PW; Giacomantonio CA
Neoplasia; 2014 Nov; 16(11):950-60. PubMed ID: 25425969
[TBL] [Abstract][Full Text] [Related]
15. Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment.
Han SJ; Sung N; Wang J; O'Malley BW; Lonard DM
Breast Cancer Res; 2022 Oct; 24(1):73. PubMed ID: 36316775
[TBL] [Abstract][Full Text] [Related]
16. An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer.
Shah M; Huang D; Blick T; Connor A; Reiter LA; Hardink JR; Lynch CC; Waltham M; Thompson EW
PLoS One; 2012; 7(1):e29615. PubMed ID: 22253746
[TBL] [Abstract][Full Text] [Related]
17. Metastasis of hormone-independent breast cancer to lung and bone is decreased by alpha-difluoromethylornithine treatment.
Richert MM; Phadke PA; Matters G; DiGirolamo DJ; Washington S; Demers LM; Bond JS; Manni A; Welch DR
Breast Cancer Res; 2005; 7(5):R819-27. PubMed ID: 16168128
[TBL] [Abstract][Full Text] [Related]
18. Treatment of established tumor is associated with ICAM-1 upregulation and reversed by CD8 depletion in a tumor necrosis factor-alpha gene transfected mouse mammary tumor.
Matory YL; Dorfman DM; Wu L; Chen M; Goedegebuure P; Eberlein TJ
Pathobiology; 1999; 67(4):186-95. PubMed ID: 10738180
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
20. Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Hiraga T; Hata K; Ikeda F; Kitagaki J; Fujimoto-Ouchi K; Tanaka Y; Yoneda T
Oncol Rep; 2005 Sep; 14(3):695-9. PubMed ID: 16077977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
